Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Active, not recruiting1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

active_not_recruiting133%
recruiting133%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruiting

Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes

NCT03473795
completednot_applicable

Tobacco Cessation Care for Cancer Patients by Automated Interactive Outreach

NCT05829824
recruiting

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

NCT06580106

Clinical Trials (3)

Showing 3 of 3 trials
NCT03473795

Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes

Active Not Recruiting
NCT05829824Not Applicable

Tobacco Cessation Care for Cancer Patients by Automated Interactive Outreach

Completed
NCT06580106

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3